ZURICH (Reuters) – Swiss pharmaceutical firm Roche isn’t planning job cuts and its enterprise is wholesome, CEO Thomas Schinecker was quoted as saying by a Swiss newspaper on Sunday.
Roche’s share value has fallen far under peaks it scaled in April 2022 and the CEO was questioned concerning the firm’s staffing plans within the context of latest setbacks in its growth of medication to deal with most cancers, amongst different sicknesses.
“The variety of employees is fixed to barely rising,” Schinecker advised the NZZ am Sonntag in an interview when requested if the corporate was planning layoffs.
“I can say with certainty that we’ve got a really wholesome enterprise. And we do not have a progress drawback both,” he mentioned, whereas noting that Roche’s funds for analysis and growth was steady and never rising.
Requested when Roche’s deliberate anti-obesity drug would hit the market, Schinecker mentioned it may very well be round 2029 or sooner.
Addressing the outlook extra broadly for subsequent yr, notably in mild of the German economic system’s latest struggles, the Roche CEO mentioned Europe nonetheless confronted challenges.
“There’s some financial progress in america, however issues are tougher in China in the mean time,” he mentioned. “And in Europe it should take a while earlier than we get out of this.”
